barchart.com
Cure8 news brief
Why This Matters
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
It also notes rising diagnoses and interest in biomarkers and new drug development that could change care over the next decade.
Who Should Pay Attention
Adult patients with Crohn’s disease, people on biologic therapies, clinicians treating IBD, patient advocates tracking drug access and cost, and researchers/industry watching the development pipeline.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
This article summarizes a market research report (DelveInsight) projecting Crohn’s disease market growth in the 7MM (US, EU4, UK, Japan) from about USD 9 billion in 2023 through 2034 and lists current and pipeline therapies.
The report highlights approved drugs, recent FDA approvals/fast-track notes, market share data (adalimumab leading in 2023), epidemiology estimates (≈2 million diagnosed prevalent cases in 7MM in 2023), and drivers of growth such as new therapies, biomarkers, and rising prevalence. It is a commercial market/forecast piece rather than a clinical study.
It names many specific drugs and companies and notes pipeline candidates and regulatory milestones (e.g., OMVOH approval, AVB-114 Fast Track). The article does not provide clinical guidance or detailed trial results.
If you want the original market tables or company breakdowns, the full DelveInsight report is behind a download/purchase link referenced in the article.
Keep In Mind
This is a commercial market forecast summarizing DelveInsight’s paid report; it compiles approvals, company activity, and pipeline lists but does not present new clinical trial data. Market predictions depend on future approvals, uptake, pricing, and healthcare policies, so they do not imply immediate changes to clinical care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationbarchart.com
Indexed viaGoogle News
Source typeBusiness news
PublishedMar 24, 2025, 1:34 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.